Research Interests:
- Assessment of host and tumor contributions to efficacy and drug resistance following antiangiogenic and immune-checkpoint treatment
- Development of clinically relevant mouse models of advanced metastatic disease
- Discovery of biomarkers to aid in clinical optimization of VEGF and PD-1 pathway inhibitor use
Biography
Dr. Ebos completed his undergraduate training at McGill University (B.Sc Biology; philosophy minor) and earned his Ph.D. in the Department of Medical Biophysics at the University of Toronto where he studied novel circulating molecules as potential surrogate markers of cancer progression and antiangiogenic drug efficacy.
Positions
Roswell Park Comprehensive Cancer Center
- Associate Professor of Oncology
- Department of Medicine
- Department of Experimental Therapeutics (Graduate Program)
- Department of Cancer Genetics and Genomics
Background
Education and Training
- PhD — Medical Biophysics, University of Toronto, Toronto, Canada
- BSc — Biology, McGill University, Montreal, Canada
Research Overview
Dr. Ebos’ laboratory currently focuses on the molecular mechanisms that drive intrinsic and acquired drug resistance to inhibitors of the tumor microenvironment and their impact on spontaneous metastatic disease. Of particular interest is the study of off-target ‘host’ effects following therapy that may alter disease progression and be exploited as biomarkers. The long-term goal of these efforts is to pair novel experimental therapeutic testing in clinically relevant preclinical models with ongoing patient trials to more readily predict subsequent/alternative therapies to improve overall efficacy.
*Currently accepting MSc, PhD, and post-doctoral trainees
View the Ebos LabFeatured on CancerTalk
Publications
Full Publications list on PubMed
- Arima J, Chida K, Wu R, Taniguchi K, McKenery A, Morreale BG, Monell AM, Abrams SI, Ebos JML, Hakamada K, Ishikawa T, Hagihara S, Kawaguchi N, Kuramoto T, Shima T, Hamamoto H, Tanaka R, Imai Y, Kimura K, Iwamoto M, Lee SW, Takabe K. ASO Author Reflections: Predictors of Immune Checkpoint Inhibitor Response in ER+/HER2- Breast Cancer: A New Role for ESR1?. Ann Surg Oncol. 2025 Sep 17;. doi: 10.1245/s10434-025-18377-4. [Epub ahead of print] PubMed PMID: 40960662.
- Arima J, Chida K, Wu R, Taniguchi K, McKenery A, Morreale BG, Monell AM, Abrams SI, Ebos JML, Hakamada K, Ishikawa T, Hagihara S, Kimura K, Iwamoto M, Lee SW, Takabe K. ESR1 Expression Negatively Correlates with Immune Cell Infiltration and Response to Immune Checkpoint Inhibitors in Estrogen Receptor-Positive/HER2-Negative Breast Cancer. Ann Surg Oncol. 2025 Sep 16;. doi: 10.1245/s10434-025-18260-2. [Epub ahead of print] PubMed PMID: 40956534.
- Dolan M, Shi Y, McKenery A, Tzetzo S, Chida K, Takabe K, Abrams SI, Ebos JML. Isolation and Ex Vivo Testing of CD8(+) T-Cell Division and Activation Using Mouse Splenocytes. Bio Protoc. 2025 Aug 20;15(16):e5423. doi: 10.21769/BioProtoc.5423. eCollection 2025 Aug 20. PubMed PMID: 40873473; PubMed Central PMCID: PMC12378427.
- Shi Y, McKenery A, Dolan M, Mastri M, Hill JW, Dommer A, Benzekry S, Long M, Abrams SI, Puzanov I, Ebos JML. Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors. EMBO Rep. 2025 Jan;26(2):521-559. doi: 10.1038/s44319-024-00333-0. Epub 2024 Dec 11. PubMed PMID: 39663510; PubMed Central PMCID: PMC11772817.
- Dolan M, Shi Y, Mastri M, Long MD, McKenery A, Hill JW, Vaghi C, Benzekry S, Barbi J, Ebos JML. A Senescence-Mimicking (Senomimetic) VEGFR TKI Side Effect Primes Tumor Immune Responses via IFN/STING Signaling. Mol Cancer Ther. 2024 Jun 19;:OF1-OF20. doi: 10.1158/1535-7163.MCT-24-0139. [Epub ahead of print] PubMed PMID: 38896060.
- Benzekry S, Mastri M, Nicolò C, Ebos JML. Machine-learning and mechanistic modeling of metastatic breast cancer after neoadjuvant treatment. PLoS Comput Biol. 2024 May;20(5):e1012088. doi: 10.1371/journal.pcbi.1012088. eCollection 2024 May. PubMed PMID: 38701089; PubMed Central PMCID: PMC11095706.
- Dolan M, Shi Y, Mastri M, Long MD, McKenery A, Hill JW, Vaghi C, Benzekry S, Barbi J, Ebos JML. A senescence-mimicking (senomimetic) VEGFR TKI side-effect primes tumor immune responses via IFN/STING signaling. Mol Cancer Ther. 2024 May 1;. doi: 10.1158/1535-7163.MCT-24-0139. [Epub ahead of print] PubMed PMID: 38690835; PubMed Central PMCID: PMC11527799.
- Boland PM, Ebos JML, Attwood K, Mastri M, Fountzilas C, Iyer RV, Banker C, Goey AKL, Bies R, Ma WW, Fakih M. A phase I/II study of nintedanib and capecitabine for refractory metastatic colorectal cancer. JNCI Cancer Spectr. 2024 Apr 30;8(3). doi: 10.1093/jncics/pkae017. PubMed PMID: 38697618; PubMed Central PMCID: PMC11065487.
- Tzetzo SL, Kramer ED, Mohammadpour H, Kim M, Rosario SR, Yu H, Dolan MR, Oturkar CC, Morreale BG, Bogner PN, Stablewski AB, Benavides FJ, Brackett CM, Ebos JML, Das GM, Opyrchal M, Nemeth MJ, Evans SS, Abrams SI. Downregulation of IRF8 in alveolar macrophages by G-CSF promotes metastatic tumor progression. iScience. 2024 Mar 15;27(3):109187. doi: 10.1016/j.isci.2024.109187. eCollection 2024 Mar 15. PubMed PMID: 38420590; PubMed Central PMCID: PMC10901102.
- Torres-Estay V, Mastri M, Rosario S, Fuenzalida P, Echeverría CE, Flores E, Watts A, Cerda-Infante J, Montecinos VP, Sotomayor PC, Amigo J, Escudero C, Nualart F, Ebos JML, Smiraglia DJ, Godoy AS. The Differential Paracrine Role of the Endothelium in Prostate Cancer Cells. Cancers (Basel). 2022 Sep 29;14(19). doi: 10.3390/cancers14194750. PubMed PMID: 36230673; PubMed Central PMCID: PMC9563990.
- Katsuta E, Sawant Dessai A, Ebos JM, Yan L, Ouchi T, Takabe K. H2AX mRNA expression reflects DNA repair, cell proliferation, metastasis, and worse survival in breast cancer. Am J Cancer Res. 2022;12(2):793-804. eCollection 2022. PubMed PMID: 35261802; PubMed Central PMCID: PMC8900000.
- He X, Zhou S, Dolan M, Shi Y, Wang J, Quinn B, Jahagirdar D, Huang WC, Tsuji M, Pili R, Ito F, Ortega J, Abrams SI, Ebos JML, Lovell JF. Immunization with short peptide particles reveals a functional CD8(+) T-cell neoepitope in a murine renal carcinoma model. J Immunother Cancer. 2021 Dec;9(12). doi: 10.1136/jitc-2021-003101. PubMed PMID: 34862254; PubMed Central PMCID: PMC8647534.
- Oshi M, Katsuta E, Yan L, Ebos JML, Rashid OM, Matsuyama R, Endo I, Takabe K. A Novel 4-Gene Score to Predict Survival, Distant Metastasis and Response to Neoadjuvant Therapy in Breast Cancer. Cancers (Basel). 2020 May 2;12(5). doi: 10.3390/cancers12051148. PubMed PMID: 32370309; PubMed Central PMCID: PMC7281399.
- Vaghi C, Rodallec A, Fanciullino R, Ciccolini J, Mochel JP, Mastri M, Poignard C, Ebos JML, Benzekry S. Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors. PLoS Comput Biol. 2020 Feb;16(2):e1007178. doi: 10.1371/journal.pcbi.1007178. eCollection 2020 Feb. PubMed PMID: 32097421; PubMed Central PMCID: PMC7059968